The presence of antibodies against pancreatic juice (PAB) in patients with Crohn's disease has recently been reported. In our study sera from 273 
of the patients with Crohn's disease had a history of pancreatic disease and of these, four had detectable pancreatic antibodies. Longitudinal observations of40 patients with Crohn's disease showed a stable pattern for PAB, independent of disease activity and treatment. Partial characterisation of the PAB antigen, isolated from pancreatic juice, showed a trypsin sensitive macromolecular protein of more than 106 daltons not identical with a panel of defined exocrine pancreatic proteins. By contrast, antibodies against goblet celis (GAB) were found in 13 of 51 patients with ulcerative colitis (29%) and in none ofthe patients with Crohn's disease or control subjects. PAB were found as a highly specific serological marker for Crohn's disease and GAB for ulcerative colitis, but the relevance of PAB and GAB in the pathogenesis in Crohn's disease remains unclear. Mayer's hemalum (Merck, Germany) for 30 seconds and mounted in Kaiser's glyceringelatine (Merck, Germany).
Antibody positive sera were diluted for reciprocal titres. Determination of immunoglobulin classes was done using monovalent antihuman immunoglobulins (Wellcome).
All slides were read under code by two different investigators. Results for PAB were considered positive if the lumen contents of pancreatic acini were labelled.
ELISA TEST PAB positive sera tested on a variety of known pancreatic antigens or partially purified pancreas antigen (see below) using an enzyme linked immunosorbent assay (ELISA). The following commercially available pancreatic proteins were used at a concentration of 5 [ig/ml: amylase, lipase, phospholipase A and C, enterokinase, carboxypeptidase A and B, chymotrypsin A and B, chymotrypsinogen, elastase, trypsin, trypsin inhibitor (Bohringer, Germany), lactoferrin (Sigma), and kallikrein (Sigma). Microtitre plates were coated with antigens in bicarbonate buffer for 20 hours at 4°C. After washing, strong PAB positive sera and control sera from patients with ulcerative colitis, pancreatitis, viral hepatitis, autoimmune diseases, and healthy subjects (1:80 diluted in PBS) were applied for one hour. After washing, peroxidase conjugated antihuman immunoglobulins (1:500 diluted) (Dakopatts, Denmark) were added and developed with orthophenyldiamine 0.05% and 0-01% H202 in citrate buffer, pH 5.0. Reaction was stopped after 20 minutes with H2S04. Analysis was done by Microelisa Auto Reader, MR 580 (Dynatech, USA) at 520 nm wave length. Tested sera were considered positive when extinction was higher than double the standard deviation of the mean extinction of 45 sera from healthy subjects. CHARACTERISATION (Fig 1) . Occasionally a weak reaction in the cytoplasm of the human acinar cells was observed as well. The pancreatic islets did not show any labelling. The same pattern was obtained using pancreatic tissue from three humans or from rats and mice (Fig 2) . Human salivary gland, breast, stomach, small and large intestine, liver, adrenal cortex, and kidney showed no fluorescence with PAB positive sera. Specific labelling of PAB serum on pancreas could be abolished after absorption with human pancreatic juice, but not with liver homogenate and bile control experiments. All results were identical, whether immunofluorescence or immunoperoxidase testing was used.
Crohn's disease patients (7%) and four of the 51 ulcerative colitis patients (8%). There was no correlation of the incidence of PAB with nuclear antibodies. In ulcerative colitis only two patients had PAB in low titres (1:20) and in other control subjects the antibody was not detected (Fig 3) . In contrast, 13 (26%) of 51 patients with ulcerative colitis and none of the 222 patients with Crohn's disease or control patients with other diseases showed fluorescence of intestinal goblet cells on cryostat sections of ileum and colon (Table I) showed thermolability when exposed to 56°C for 30 minutes. Detergents (sodium dodecylsulphate, Tritonx 100, and Tween 20 concentrations of 1%) and ethanol 95% and chloroform acetone (1:2) had no effect on antigenic activity.
CORRELATION OF PAB WITH CLINICAL FEATURES
Effect ofenzyme treatment on antigenic activity The reactivity of 208 sera from patients with Crohn's disease and 135 sera from patients with other diseases (ulcerative colitis, acute and viral hepatitis, autoimmune diseases, pancreatitis) and healthy controls were tested in an ELISA system using chromatographically purified pancreatic antigen which was either native or had been treated with various enzymes (Table II) before coating the microtitre plates. When native antigen was used for testing, 54 (26%) of the patients with Crohn's disease showed a positive reaction but also two of 25 (8%) patients with ulcerative colitis, three of nine (33%) patients with acute and chronic viral hepatitis, and two of 53 (4%) control patients. The relation of the results of ELISA and immunocytochemistry is shown in Table III .
The ELISA using the chromatographically purified antigen is less sensitive for PAB detection in Crohn's disease than the immunofluorescence test. Furthermore, ELISA also detected 'PAB reactivity' in some sera from patients with ulcerative colitis, pancreatitis, viral hepatitis, and healthy controls, although previous immunofluorescence showed no reactivity.
When microtitre plates that had been coated with pancreatic antigen after digestion with Healthy control subjects 53 0 2 0 Figure 5 : Detection ofantibodies to a pancreatic antigen (PAB) using an ELISA system. Microtitre plates were coated with chromatographically purified antigen, either native or treated with trypsin. Using the trypsin treated antigen only PAB in sera from patients with Crohn's disease lose their reactivity, not PAB in sera from patients with hepatitis or ulcerative colitis.
various enzymes were used, after trypsin treatment the positive reactivity of sera containing PAB from patients with Crohn's disease was abolished, but not when sera containing PAB from other patients were tested (Fig 5) . Treatment with all other enzymes did not influence the reactivity ofPAB positive sera from patients with any of the diseases tested (Table II) . To clarify the question of why PAB occurs in Crohn's disease, it is essential to define exactly the nature of the antigenic determinants reacting with those antibodies. Our results so far show that the antigenic site of the pancreatic macromolecule, as it has been prepared from pancreatic juice, is a protein since it was completely destroyed by trypsin digestion. In contrast some PAB found in sera from patients with 'nonCrohn's disease' by ELISA reacted obviously with other determinants of this macromolecule, as trypsin treatment did not influence their reactivity. This emphasises the unique specificity for PAB in Crohn's disease. Our preliminary characterisation allows the development of a specific ELISA for PAB detection and further investigation of their role in Crohn's disease.
